cbdMD Inc
AMEX:YCBD
Relative Value
The Relative Value of one YCBD stock under the Base Case scenario is 4.5 USD. Compared to the current market price of 0.68 USD, cbdMD Inc is Undervalued by 85%.
Relative Value is the estimated value of a stock based on various valuation multiples like P/E and EV/EBIT ratios. It offers a quick snapshot of a stock's valuation in relation to its peers and historical norms.
Multiples Across Competitors
YCBD Competitors Multiples
cbdMD Inc Competitors
| Market Cap | P/S | P/E | EV/EBITDA | EV/EBIT | ||||
|---|---|---|---|---|---|---|---|---|
| US |
c
|
cbdMD Inc
AMEX:YCBD
|
6.8m USD | 0.4 | -1.8 | -2.7 | -1.5 | |
| US |
|
Eli Lilly and Co
NYSE:LLY
|
856.7B USD | 13.1 | 41.5 | 28 | 29.9 | |
| US |
|
Johnson & Johnson
NYSE:JNJ
|
566.8B USD | 6 | 21.1 | 14.7 | 18.1 | |
| CH |
|
Roche Holding AG
SIX:ROG
|
243.3B CHF | 4 | 18.9 | 11.2 | 12.6 | |
| UK |
|
AstraZeneca PLC
LSE:AZN
|
216.4B GBP | 4.9 | 28.3 | 15.7 | 22.2 | |
| US |
|
Merck & Co Inc
NYSE:MRK
|
282.6B USD | 4.3 | 15.5 | 9.6 | 11.7 | |
| CH |
|
Novartis AG
SIX:NOVN
|
222.2B CHF | 5.1 | 20.5 | 12.7 | 16.3 | |
| IE |
E
|
Endo International PLC
LSE:0Y5F
|
237.1B USD | 102.3 | -81.1 | 375.3 | 941.3 | |
| DK |
|
Novo Nordisk A/S
CSE:NOVO B
|
1.1T DKK | 3.4 | 10.3 | 7.7 | 9 | |
| US |
|
Pfizer Inc
NYSE:PFE
|
153.4B USD | 2.5 | 19.7 | 7.6 | 10.1 | |
| US |
|
Bristol-Myers Squibb Co
NYSE:BMY
|
115.7B USD | 2.4 | 16.4 | 7 | 8.6 |